Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials.
Whole-body MRI (WB-MRI) allows imaging of a large volume of the body in a single image acquisition session. It has been extensively investigated for the detection and staging of visceral and osseous tumors [1] [2] [3] [4] [5] [6] and is well-suited to tumor syndromes including neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), [7] [8] [9] as these patients often have a high burden of tumors as well as large tumors that cross anatomic planes (figure). WB-MRI has been used to evaluate tumor burden and to characterize neoplasms in patients with NF syndromes [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and is being used in some clinical trials to evaluate response to therapy (NCT01207687). A uniform image acquisition protocol and interpretation method would enable WB-MRI to be used as a key endpoint to assess tumor treatment response in multicenter clinical trials for NF-associated peripheral nerve sheath tumors (PNST). However, thus far, variable approaches have been used for WB-MRI acquisition and image analysis in NF.
The WB-MRI Working Group was formed as part of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration to generate consensus recommendations and identify priority areas for future research regarding WB-MRI as applied to NF clinical trials. The working group reviewed the existing literature on the use of WB-MRI in patients with NF1, NF2, and SWN to evaluate differences in image acquisition (including magnet strengths, imaging planes, and 2D vs 3D approaches); assess the feasibility, reproducibility, and diagnostic accuracy of WB-MRI in people with NF; and evaluate the benefits of functional MRI techniques, such as diffusion-weighted imaging (DWI) with quantitative apparent diffusion coefficient (ADC) maps and contrast-enhanced imaging for NF-associated PNST. We used this information to recommend best practices for WB-MRI for use in NF clinical trials and to establish research priorities for future studies.
METHODS A computer-aided search of PubMed/MEDLINE from inception to May 2015 was conducted to find relevant English language publications on WB-MRI and NF syndromes. To expand our search, bibliographies of retrieved articles were screened for additional citations. A single reviewer (S.A.) independently screened titles, abstracts, full articles, and references to determine eligibility for inclusion. Studies were included if they had a prospective or retrospective study design with patients of any age with NF1, NF2, and SWN using WB-MRI in which at least the area from the neck to the pelvis was imaged. Review articles, meta-analyses, abstracts, case reports, or case series of less than 10 patients, guidelines, or studies performed in animals were excluded.
Inclusion of patients based on well-established clinical criteria for the NF syndromes was adequate for selection of the patient population, given that pathologic confirmation of each neoplasm is not feasible. [7] [8] [9] All included articles were analyzed for diagnosis (NF1, NF2, and SWN), index test (WB-MRI), and reference test (clinical criteria for diagnosis of the NF syndromes). The following information was extracted from articles: author name, year of publication, number of participants, specific tumor syndrome, magnet strength (1.5T vs 3.0T), specific WB-MRI techniques (2D vs 3D imaging, specific imaging sequences, inclusion of functional MRI sequences, contrast administration), sex, mean age with SD, quantification of PNST size (2D vs volumetric), and types of tumors (malignant vs benign PNST). WB-MRI studies were also classified by clinical indication into 3 categories: tumor detection (including extent of disease), tumor characterization, or response to therapy.
RESULTS
The literature search yielded 25 articles. After full review of the articles, 14 studies met all inclusion criteria. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Two studies were excluded as they discussed extratumoral findings (i.e., incidental findings on WB-MRI in NF or marrow changes in patients with NF treated with imatinib mesylate 22, 23 ). Hence, the final analysis included 12 studies. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] WB-MRI acquisition protocols. Table 1 summarizes the information extracted from the investigations that met inclusion criteria. Of the 12 publications, 11 employed 1.5T magnet strength [10] [11] [12] [14] [15] [16] [17] [18] [19] [20] [21] ; only 1 study used 3.0T magnet. 13 One study performed at 3.0T acquired volumetric 3D images with isotropic resolution in the coronal plane and generated multiplanar reformations (MPR) in sagittal and axial plane with good diagnostic quality. 13 The remainder of the WB-MRI investigations utilized 2D acquisitions in the coronal plane alone, or in both coronal and axial planes. All investigations included a short tau inversion In both images, the range of field of view is apparent depending on the table length and the size of the person being imaged and in both images several tumors distributed across anatomic regions can be identified. In (B), some of the artifact that can occur affecting interpretation is apparent.
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Neurology 87 (Suppl 1) August 16, 2016 recovery (STIR) sequence. Only 1 trial performed functional MRI with quantitative DWI and ADC maps. 13 DWI technique included 3 b values and was performed with slice thickness of 5 mm. 13 Three of the 12 studies used contrast material as an adjunct to traditional WB-MRI fluid-sensitive sequences. 11, 13, 14 One study obtained postcontrast 3D volumetric gradient echo images 13 while the other study obtained 2D spin echo T1-weighted images with fat suppression. 14 14, 15, 17, 18, 21 while 5 of the 12 publications used a computerized 3D-volumetry method developed for WB-MRI using the dynamic threshold level set method. [10] [11] [12] 16, 19 There are limited data with regards to characterization of neoplasms as benign or malignant and no data to date Abbreviations: ADC 5 apparent diffusion coefficient; DWI 5 diffusion-weighted imaging; FOV 5 field of view; IR 5 inversion recovery; NF 5 neurofibromatosis; PNST 5 peripheral nerve sheath tumors; STIR 5 short tau inversion recovery; TE 5 echo time; TR 5 repetition time; VIBE 5 T1-weighted sequences (volume interpolated breath-hold examination); WB-MRI 5 whole-body MRI. a A plane of imaging is not specified.
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ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. for assessment of treatment response, although such analysis is ongoing in a clinical trial assessing WB-MRI over time in people with NF2 treated with bevacizumab (NCT01207687). The data from tables 1 and 2 were critically evaluated to generate knowledge gaps and future directions for WB-MRI investigations to provide the required metrics for inclusion of WB-MRI as a primary endpoint in clinical trials for NF-associated PNST. Priority areas identified include WB-MRI reproducibility for anatomical measures, optimal analysis techniques, and establishing the minimal meaningful clinical difference in tumor size (table 3) . DISCUSSION WB-MRI provides continuous coverage of lesions that cross anatomical boundaries and therefore cannot be fully imaged with localized MRI, a significant advantage when evaluating patients with NF syndromes where there are frequently large infiltrative tumors (figure) or multifocal PNST, which may be missed without WB-MRI assessment. 21 In this setting, WB-MRI allows assessment of differential response within and across tumors over time. An additional advantage is that WB-MRI can be completed with a typical scan time of 45-60 minutes on both 1.5T and 3.0T systems and uses the same protocols for patients of all ages, allowing continuity across and within patients enrolled in a therapeutic trial. 12, 13, 18 A major goal of this work was to identify core aspects of WB-MRI application for assessment of NFassociated PNST to enable inclusion of WB-MRI as a primary endpoint for therapeutic trials of NFassociated PNST. There are no comparative data available with respect to magnet strength, image acquisition plane (axial vs coronal), 2D or 3D acquisition, or the value of functional imaging and administration of contrast material available across all available investigations. However, after the analyses of the WB-MRI studies in patients with NF conducted to date, several statements can be made: WB-MRI in NF is feasible both at 1.5T or 3.0T; it can be standardized across multiple sites for anatomic tumor assessment in the setting of a clinical trial; both 2D and 3D acquisition are operational for generating tumor data; STIR is a core sequence for evaluation of tumor burden; and functional sequences such as DWI can be considered in the setting of WB-MRI. Outside of these statements, the WB-MRI Working Group of REiNS is not able to make specific recommendations for acquisition protocols at this time due to a lack of data. For example, only a single case series of 4 patients compared analysis of tumor burden in patients with NF1 who underwent WB-MRI on both 1.5T and 3.0T within a 6-month period. 24 This study showed no difference in tumor volumes between the 2 magnet strengths; however, there are no other comparative analyses and this study is too small to draw conclusions. The majority of studies completed to date use 1.5T as this is more widely available. The wide availability of 1.5T magnets is an advantage for application of WB-MRI to multicenter trials. However, 3.0T WB-MRI has theoretical advantages, such as increased signal to noise ratios (SNR), allowing for improved 3D sequences as well as allowing for DWI acquisition in an acceptable imaging time. Potential disadvantages of 3.0T MRI include B1 field inhomogeneities and susceptibility artifacts. 2, 13 Work is ongoing to optimize this with technological advances such as continuous table motion and improved coils, which are expected to shorten acquisition and increase SNR. 2, 25 With respect to specific sequences, the STIR sequence, with its combined T1 and T2 weighting, has been uniformly used in the WB-MRI investigations for PNST. Most pathologic processes, including tumors, are proton-rich with resultant prolonged T1 and T2 relaxation times and increased signal intensity on STIR images. In addition, fat suppression is more robust and homogeneous on inversion recovery sequences than other frequency selective sequences. These features make the STIR sequence valuable for detection and measurement of PNST and a core sequence for assessment of whole body tumor burden in NF. However, detection of other pathologies in the viscera or the skeletal system may require additional imaging.
Regarding 2D and 3D acquisitions, 11 of the 12 studies used 2D imaging sequences, 10-12,14-21 while only 1 study (at 3.0T) obtained images with 3D volumetric sequences. 13 This allows us to say that both are feasible, but there are no data to suggest advantages of one over the other. There are important differences in spatial resolution between 2D and 3D sequences. For 2D sequences obtained at 1.5T, the in-plane resolution can be 0.3-1.5 mm and the slice thickness can range from 5 to 10 mm with no interslice gap. WB-MRI at this resolution may not be adequate for the detection or characterization of very small neoplasms and PNST located in the skin and subcutaneous tissues. 3D sequences obtained at 3.0T can have an interpolated spatial resolution of 2 mm with slice thickness of 2 mm and no interslice gap. 13 Both 2D and 3D sequences can also be performed with higher spatial resolution, but at the cost of longer acquisition time. A potential advantage of 3D sequences includes MPR capabilities such that a 3D isotropic dataset can be displayed in any imaging plane. However, 3D acquisition may not be available on all scanners, limiting application in multicenter studies. For both 2D and 3D sequences, there is a lack of consensus regarding an optimal imaging plane. Although all WB-MRI investigations to date have included the coronal plane, no comparative study has been performed to determine the ideal imaging plane. An advantage of coronal image acquisition is that for anatomic sequences such as STIR or T1weigted imaging, there is less respiratory motion due to faster image acquisition. Of note, the coronal image acquisition may not be optimal for DWI, particularly in the neck and thoracic regions, due to cardiac motion.
There is also a lack of data regarding the added value of IV contrast material. Use of exogenous contrast requires venous access and hemodynamic monitoring during the WB-MRI acquisition that may reduce feasibility and carries the additional risk of nephrogenic systemic fibrosis in the setting of renal failure. New literature also suggests a relationship between repetitive gadolinium exposure and high signal intensity in the basal ganglia, further raising concern about exogenous contrast. 26 There are currently insufficient data to assess the potential diagnostic benefit vs risk of the use of IV contrast for PNST. Finally, no investigations have been performed to assess the added value of DWI with ADC maps to standard sequences in WB-MRI in patients with NF. This is feasible and the potential advantages include the assessment of tumor biology and possibly treatment response, the ability to distinguish a cyst from a neoplasm, and the characterization of incidental findings. For example, specific threshold ADC values enable distinguishing soft tissue masses from cysts with high specificity (100%), important when quantifying tumor burden. 13, 27 Similarly, there is localized MRI experience using DWI and ADC mapping for PNST characterization as benign or malignant with 100% sensitivity (95% confidence interval 66.4%-100%) and 77% specificity. 28 There is also limited experience comparing WB-MRI with whole body 18F-fluorodeoxyglucose (FDG) PET/CT for characterizing PNST as benign or malignant. 14 Although 18F-FDG PET/CT had higher sensitivity (100%) compared with WB-MRI (66.7%) on a per lesion basis, WB-MRI had a higher specificity (97% for WB-MRI vs 74.4% for 18F-FDG PET/CT) for detecting malignancy. 14 WB-MRI in this particular investigation used routine anatomic sequences only, 14 and thus it remains to be determined whether addition of quantitative functional MRI sequences with ADC measurements would alter the diagnostic accuracy for detection of malignancy.
Although WB-MRI with functional sequences for detection and characterization of benign vs malignant PNST shows promise, currently these sequences can be difficult to perform uniformly across multiple sites. No investigations have been published to date regarding the assessment of treatment response in PNST in NF, but there are efforts currently for analysis of ongoing therapeutic studies with pretreatment and posttreatment WB-MRI (NCT01207687). This study will also allow assessment of the added value of functional MRI or contrast-enhanced sequences for assessing changes in tumor biology independent of changes in tumor size.
With respect to WB-MRI analysis, the field has recommended volumetric measurements of tumor rather than 2D measures. [29] [30] [31] Tumor volumetry is preferred for quantifying complex PNST such as plexiform neurofibromas that can be large and infiltrative whereas 2D or linear measurement is more likely to misrepresent the true tumor dimensions by overestimating or underestimating PNST size and can be fraught with interobserver and intraobserver variations. [32] [33] [34] Tumor volumetry, particularly in infiltrative plexiform neoplasms such as the ones identified in patients with NF syndromes, has become the optimal approach for assessing tumor burden. In addition, the current therapeutic trials in NF syndromes use volumetric analysis as a primary or secondary endpoint (NCT01362803, NCT02101736, NCT02096471). Volumetric tumor burden can be measured manually, though this is timeconsuming and impractical for routine clinical evaluation. Computer-aided tumor segmentation of PNST can be performed on MRI sequences that show clear distinction between tumor and surrounding normal tissue, such as STIR or similar fluid sensitive sequences. In one study comparing manual and semiautomated tumor volumetry, computerized volumetry using a dynamic threshold method was superior to manual segmentation techniques. 19 Moreover, computerized volumetry was reliable and less labor intensive, which made it more repeatable compared to manual segmentation. 19 It is important to note that reliability and repeatability were calculated using a small sample size 19 ; however, this technique has subsequently been applied in larger studies of approximately 250 patients. [10] [11] [12] A multicenter study comparing the 2 principal semi-automated methods for reliability and interpretation time compared with the manual technique in lesion detection and change in lesion size is currently underway.
Although there are several advantages to WB-MRI for NF, there are also important limitations. First, for very tall or large individuals, portions of the body may not be adequately imaged, including the distal legs, shoulders, and arms. Adequate imaging of the distal lower extremities is a particular concern for 3.0T scanners and may limit the use of WB-MRI if there are tumors of interest in these regions. This can be addressed by imaging the upper and lower body separately; however, this increases cost and time. An additional concern for tumor assessment with WB-MRI is that the lower limit of tumor volume that can be assessed has not been described, and depending on the WB-MRI technique as well as the tumor distribution, the cutoff value may be variable. Selecting the same PNST for contouring consistently over consecutive scans is crucial for determining size change and can only be done on comparable quality image sets. Similarly, diagnostic performance of WB-MRI for total tumor burden estimates is dependent on the correct representation of the body on the MRI and needs to be standardized across sites and time points. Importantly, WB-MRI can suffer from varied image distortions at the periphery of the imaging field, which may lead to measurement errors. 13 Given spatial resolution limitations and depending on what sequences are applied, additional dedicated MRI sequences such as magnetic resonance neurography may be necessary to provide improved anatomic and functional characterization of PNST, 35 evaluate tumors in and around the spinal cord, identify small tumors such as pheochromocytomas, or diagnose vascular anomalies. Finally, it is worth noting that there are some limitations to the analysis presented based on the very limited literature on this topic. Only 14 investigations fulfilled search criteria. Of these, several studies had overlapping patient data and WB-MRI protocols reported with separate endpoints. 10, 16, 19 This further highlights the need for additional research on WB-MRI performance in NF syndromes (table 3) .
Choosing standardized image acquisition and analysis methods is essential for optimal multicenter collaboration applying WB-MRI as a tool for assessing tumors in NF. WB-MRI may serve as either a primary or secondary endpoint in clinical drug trials that target multiple tumors requiring systemic rather than localized imaging. The systematic process developed by the REiNS WB-MRI Working Group has enabled a multicenter conversation about imaging protocols and the development of future comparative projects. These results will be used by the group to identify the most appropriate WB-MRI acquisition and interpretation methods for individuals with NF syndromes in future clinical trials and prioritize research questions about the optimal use of WB-MRI as an endpoint measure in NF research.
